Articles, Case Studies and Resources | Acumetis

How most favored nation policy is reshaping pharmaceutical pricing and market access

Discover how Most Favored Nation (MFN) policy impacts U.S. drug pricing and market access, from CMS enforcement to launch planning. Get the whitepaper now.

Why direct-to-patient is not one-size-fits-all

Explore scalable direct-to-patient (DTP) models that improve affordability, time-to-therapy, and patient engagement with a strategic, data-driven approach.

Meet Acumetis at ISPOR U.S. 2026!

Acumetis will be attending ISPOR U.S. 2026 in Philadelphia, the leading global conference for Health Economics and Outcomes Research (HEOR) and market access strategy.

Direct-to-patient (DTP) readiness assessment

We created a direct-to-patient (DTP) readiness assessment tool that distills complex market and patient dynamics into a clear readiness signal. This fact based tool enables you to assess your product...

Start the assessment now

Most favored nation (MFN) exposure assessment

Implementation of a Most Favored Nation policy creates a great deal of uncertainty. We built this tool to help understand the impact for your business.

Calculate your impact now

JCA readiness assessment

New HTA process requires transformation of internal infrastructure and organization.Take our JCA Readiness assessment, to highlight the unique gaps and advice on the next steps to make sure you are...

Start the assessment now

How go/no-go assessment supports strategic decision-making

Learn how go/no-go assessments evaluate market access, pricing, and value drivers to guide strategic decisions for pipeline products.

How PICO prediction supports JCA strategy and submission

Learn how PICO Prediction guides JCA evidence alignment, supports multi-market HTA planning, and strengthens submission strategy.